MS-275 to modulate NK cell response against Osteosarcoma.
Implication of the chemokines CXCL9/CXCL10
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Osteosarcoma (OS) is the most common
primary malignant bone tumor in children and
adolescents. It often metastasizes to the
lungs and there are currently no good
therapies for relapsed/metastatic disease.
Immunotherapy might offer a hidden benefit.
Natural Killer (NK) cells have already shown
benefit in the treatment of various cancers
including OS. Therapeutic effect has been
limited by the inability of NK cells to penetrate
within the tumor due in part to the harsh tumor
microenvironment (TME). The TME is
hypoxic, inhibits NK cell penetration and
contains cytokines which promote metastasis
and maintains the stemness of tumor cells.
Histone Deacetylase Inhibitors (HDACs) have
been used to overcome the harsh TME. MS275/Entinostat is an HDAC that has been
shown increase OS tumor cell susceptibility to
NK cell lysis.2 Additionally, our laboratory has
preliminarily demonstrated that pre-treatment
of NK cells with MS-275 enhances NK cells
therapeutic efficacy against OS lung
metastases. However, whether this effect is
due in part by the ability of MS-275 to
modulate
the
expression/secretion
of
chemokines, such as CXCL9 and/or CXCL10,
known to participate in NK cells migration, is
not known.
CXCL9, is involved in the accumulation of γδT
cells whereas CXCL10-controlled NK cell
recruitment has been correlated with tumor
regression, increased number of NK cells,
and a good prognosis.3 CXCL9/10 bind the
CXCR3 receptor on NK cells, which has also
been shown to play a role in tumor
suppression. 4 The purpose of this study was
to determine whether pre-treatment of NK
cells with MS-275 will enhance chemokine
expression/release by OS tumor cells and
therefore contribute to the enhanced
therapeutic effect seen preliminarily in vivo.
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• Transwell assay. MS-275 untreated and treated NK cells were added to the transwell
inserts with polycarbonate membranes and OS-17 cells were used as a migratory stimulus.
The number of NK cells (untreated and MS275 pre-treated) that remained at the bottom of
the membrane or present in the OS media were counted by OD and Vi-CELL respectively.

- MS-275 treatment of NK cells does not alter NK cells migration
towards the OS-17 OS cells
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Fig. 3 There is no significant difference in the migration of
untreated NK and MS-275-treated NK cells towards OS-17 OS cells
(A) Optical density of untreated NK and MS-275 treated NK cells
detected within the membrane of the transwell insert. (B) Number
of untreated and MS-275 treated NK cells that migrated through
the transwell insert to the OS-17 culture media.

• Chemokine Array. Supernatant of OS-17 cells co-cultured with untreated and MS275-pretreated NK cells was collected and CXCL9/10 expression was measured by
chemiluminescent imaging and quantified by densitometry. Percent increase/decrease of
normalized signal intensity was calculated by X(Ny)= X(y) * P1/P(y). Where P1= mean
signal density of Positive Control spots on reference OS+ NK array, P(y)= mean signal
density of positive control spots on OS+ MS-275NK array, X(y)= X(Ny)= normalized signal
intensity for spot “X” on Array “y”.

Results
- Pre-treatment of NK cells with MS-275 does not change OS17 OS cells
CXCL9 expression as compared to untreated NK cells.
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- Soluble CXCL9/10 is altered in the media of OS-17 cells co-cultured with
MS-275 pretreated NK cells
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- Pre-treatment of NK cells with MS-275 does not change OS17 OS cells
CXCL10 expression as compared to untreated NK cells.
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Fig. 5 NK cells CXCR3 expression measured under different conditions with no significant change. Flow cytometry was used to measure CXCR3 expression
On untreated NK and MS275-NK cells exposed to OS17 cells.

Conclusions

Fig. A Expression of CXCL9/10 on OS-17 cells was
determined by immunocytochemistry

• Exposure of OS17 osteosarcoma cells to NK cells increases CXCL9 and CXCL10 expression
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• Epigenetic modulation of NK cells by MS-275 does not provide additional effect on chemokine (CXCL9
& CXCL10) release and/or expression by OS tumor cells.
• Migratory capacity of NK cells is not enhanced by pre-treatment with MS-275.
• Chemokines might not play a major role in the enhanced therapeutic effect seen when tumors are
treated with MS-275 pre-treated NK cells as compared to the untreated NK cells.
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Fig. B OS cells in each flask were collected and tested for
CXCL9/10. NK cells were collected and tested for CXCR3.
Both were then examined by flow cytometry
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- Expression of CXCR3 is not changed on untreated and MS-275 treated NK
cells after exposure to OS17 OS cells
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• Flow cytometry (Fig.B) MS-275 pretreated
and untreated NK cells were co-cultured
with OS-17 cells. OS-17 cells were
collected, and CXCL9/10 expression
determined. CXCR3 expression was also
measured on un-treated and pretreated
MS-275 NK cells cultured alone or after
exposure to OS17 cells and results
compared.
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Fig. 4 Chemokine array demonstrates a decrease in soluble CXCL9 and an increase in soluble CXCL10. Supernatant from untreated-NK +OS17 and MS275
pre-treated-NK + OS17 was collected, and sCXCL9/10 measured by (A) Chemiluminescent imaging and (B) quantified by densitometry (see methods).

Fig. 1 CXCL9 expression was unchanged between OS-17+NK co-cultured and MS-275NK+ OS-17 co-cultured. OS-17 cells cultured
alone displayed low levels of CXCL9 shown by (A/B) Immunocytochemistry and (C/D) Flow cytometric analysis

• Immunocytochemistry (Fig. A) NK cells
were expanded from buffy coats as
previously described.1 NK cells were then
treated with 0.5uM MS-275 for 24 hours
and then co-cultured with OS-17 cells
seeded 24 hours prior, at a 2.5 to 1 effector
(NK) to target (OS-17 cells) ratio.
Expression of CXCL9/10 on OS-17 cells
was determined by immunocytochemistry
24 hours later.
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Fig. 2 CXCL10 expression was unchanged between OS-17+NK co-cultured and MS-275NK+ OS-17 co-cultured. OS-17 cells cultured
alone displayed low levels of CXCL10 shown by (A/B) Brightfield microscopy and (C/D) Flow cytometric analysis
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